Olimel N12e

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, the active ingredients in Olimel N12e, are essential amino acids presented as an injectable solution for intravenous use. It supports protein synthesis and provides nutritional support for patients requiring parenteral nutrition, such as those in intensive care, postoperative recovery, or with severe malabsorption.

GNH USA supplies Olimel N12e as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Olimel N12e is used as part of parenteral nutrition to address protein and amino‑acid deficiencies in several clinical situations. - Critical illness: supplies essential amino acids to maintain nitrogen balance and support tissue repair. - Post‑operative recovery: provides rapid protein replenishment to accelerate wound healing and reduce catabolism. - Severe malabsorption: delivers nutrients directly into the bloodstream when gastrointestinal uptake is compromised. - Chronic renal or hepatic failure: offers a controlled amino‑acid profile to meet metabolic needs while limiting toxic metabolites. - Severe burns: delivers amino acids to support extensive tissue repair. - Trauma patients: helps maintain nitrogen balance during high metabolic demand.

Intravenous administration of amino‑acid mixtures can be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hyperglycemia: transient increase in blood glucose levels. - Electrolyte imbalance: mild shifts in potassium or phosphate. - Nausea or vomiting: gastrointestinal discomfort following infusion. - Local infusion site irritation: redness or mild pain at the catheter site. - Fever: low‑grade temperature rise. - Renal dysfunction: impaired kidney function in susceptible patients.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention. - Metabolic acidosis: significant pH alteration due to excessive amino‑acid load. - Hyperosmolarity: elevated serum osmolarity leading to neurologic symptoms. - Thrombophlebitis: inflammation of the vein associated with catheter use. - Renal dysfunction: worsening kidney function in patients with pre‑existing renal disease. - Severe electrolyte disturbances: dangerous shifts in potassium, calcium, or phosphate levels.

When using Olimel N12e, clinicians should observe several precautionary measures to ensure patient safety and product integrity. - Assess renal and hepatic function: adjust infusion rates based on organ performance. - Monitor blood glucose: amino acids may affect glycemic control, especially in diabetic patients. - Check electrolyte levels: regular labs help detect imbalances during therapy. - Observe for signs of hypersensitivity: discontinue infusion if rash, itching, or respiratory distress occur. - Avoid concurrent high‑protein oral supplements: may lead to excess nitrogen load. - Verify compatibility with other IV solutions: avoid mixing with calcium or phosphate containing fluids. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Amino‑acid solutions can interact with certain medications and clinical conditions, requiring careful management.

Major Interactions (Avoid): - High‑dose insulin therapy: concurrent infusion may exacerbate hypoglycemia. - Loop diuretics: increased risk of electrolyte disturbances, especially potassium loss. - Calcium‑containing solutions: may precipitate when mixed with certain amino‑acid formulations. - Concurrent high‑dose vitamin C: may increase risk of oxalate precipitation. - Sodium bicarbonate infusions: can alter solution pH and affect stability.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenobarbital): may alter amino‑acid metabolism. - Steroids: can increase protein catabolism, affecting the intended benefit. - Parenteral lipid emulsions: co‑administration requires monitoring of osmolarity and caloric balance. - Renal replacement therapy: monitor amino‑acid clearance and adjust dosing. - Vasopressors: may affect peripheral circulation and infusion site tolerance.